{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:27:54Z","timestamp":1789140474740,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vonoprazan is more potent and longer acting than traditional proton pump inhibitor. Although vonoprazan is expected to be superior to proton pump inhibitor, its efficacy in the treatment of gastric ulcers following endoscopic submucosal dissection (ESD) is not fully understood. The aim of this study was to evaluate the effectiveness of vonoprazan in artificial ulcer healing following ESD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with gastric tumors were randomly assigned to the vonoprazan group (group V) or lansoprazole group (group L) after ESD. Patients received intravenous lansoprazole (30\u00a0mg) twice on the day of ESD. Thereafter, patients were treated with vonoprazan (20\u00a0mg\/day) in group V or lansoprazole (30\u00a0mg\/day) in group L. Esophagogastroduodenoscopy was performed 4 and 8\u00a0weeks after the ESD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 168 patients were analyzed. The 4-week healing rate for artificial ulcer was not significantly higher in group V versus group L (17\/85, 20.0% vs. 14\/83, 16.9%, respectively). In addition, there were no significant differences between the 4-week shrinkage rates between the two groups. Postoperative bleeding occurred in none of the patients in group V and three in group L. One patient in group V presented delayed perforation 2\u00a0days after ESD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Vonoprazan might not be superior to lansoprazole in the healing of artificial gastric ulcer after ESD.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: University hospital Medical Information Network (registration number: UMIN000016642), Registered 27 February 2015, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.umin.ac.jp\/ctr\/index-j.htm.\">https:\/\/www.umin.ac.jp\/ctr\/index-j.htm.<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01822-5","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T19:02:39Z","timestamp":1621710159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Daisuke","family":"Kawai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Okanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Gotoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tsugeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeatsu","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"1822_CR1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/gut.48.2.225","volume":"48","author":"H Ono","year":"2001","unstructured":"Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48:225\u20139.","journal-title":"Gut"},{"key":"1822_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.gie.2005.08.002","volume":"63","author":"M Fujishiro","year":"2006","unstructured":"Fujishiro M, Yahagi N, Nakamura M, Kakushima N, Kodashima S, Ono S, et al. Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc. 2006;63:243\u20139.","journal-title":"Gastrointest Endosc"},{"key":"1822_CR3","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.gie.2008.09.027","volume":"69","author":"IK Chung","year":"2009","unstructured":"Chung IK, Lee JH, Lee SH, Kim SJ, Cho JY, Cho WY, et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc. 2009;69:1228\u201335.","journal-title":"Gastrointest Endosc"},{"key":"1822_CR4","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1055\/s-0030-1255668","volume":"42","author":"A Probst","year":"2010","unstructured":"Probst A, Pommer B, Golger D, Anthuber M, Arnholdt H, Messmann H. Endoscopic submucosal dissection in gastric neoplasia-experience from a European center. Endoscopy. 2010;42:1037\u201344.","journal-title":"Endoscopy"},{"key":"1822_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.5946\/ce.2014.47.5.398","volume":"47","author":"I Saito","year":"2014","unstructured":"Saito I, Tsuji Y, Sakaguchi Y, Niimi K, Ono S, Kodashima S, et al. Complications related to gastric endoscopic submucosal dissection and their managements. Clin Endosc. 2014;47:398\u2013403.","journal-title":"Clin Endosc"},{"key":"1822_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, Munson K, Strugatsky D, Tokhtaeva E, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412\u201320.","journal-title":"J Pharmacol Exp Ther"},{"key":"1822_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"1822_CR8","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.bcp.2011.02.009","volume":"81","author":"J Matsukawa","year":"2011","unstructured":"Matsukawa J, Hori Y, Nishida H, Kajino M, Inatomi N. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011;81:1145\u201351.","journal-title":"Biochem Pharmacol"},{"key":"1822_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.cct.2006.05.002","volume":"27","author":"A Endo","year":"2006","unstructured":"Endo A, Nagatani F, Hamada C, Yoshimura I. Minimization method for balancing continuous prognostic variables between treatment and control groups using Kullback-Leibler divergence. Contemp Clin Trials. 2006;27:420\u201331.","journal-title":"Contemp Clin Trials"},{"key":"1822_CR10","first-page":"198","volume-title":"Ulcer of the stomach and duodenum","author":"T Sakita","year":"1971","unstructured":"Sakita T, Fukutomi H. Endoscopic diagnosis. In: Yoshitoshi Y, editor. Ulcer of the stomach and duodenum. Tokyo: Nankodo; 1971. p. 198\u2013208."},{"key":"1822_CR11","first-page":"1270","volume":"56","author":"Y Asakuma","year":"2009","unstructured":"Asakuma Y, Kudo M, Matsui S, Okada M, Kawasaki M, Umehara Y, et al. Comparison of an ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers in early gastric cancer: prospective randomized study. Hepatogastroenterology. 2009;56:1270\u20133.","journal-title":"Hepatogastroenterology"},{"key":"1822_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00535-009-0157-0","volume":"45","author":"T Kato","year":"2010","unstructured":"Kato T, Araki H, Onogi F, Ibuka T, Sugiyama A, Tomita E, et al. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection\u2014a randomized controlled study. J Gastroenterol. 2010;45:285\u201390.","journal-title":"J Gastroenterol"},{"key":"1822_CR13","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1007\/s10620-018-4948-0","volume":"63","author":"A Hirai","year":"2018","unstructured":"Hirai A, Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, et al. Comparison of the effects of vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers. Dig Dis Sci. 2018;63:974\u201381.","journal-title":"Dig Dis Sci"},{"key":"1822_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2169\/internalmedicine.1146-18","volume":"58","author":"T Ichida","year":"2019","unstructured":"Ichida T, Ueyama S, Eto T, Kusano F, Sakai Y. Randomized controlled trial comparing the effects of vonoprazan plus rebamipide and esomeprazole plus rebamipide on gastric ulcer healing induced by endoscopic submucosal dissection. Intern Med. 2019;58:159\u201366.","journal-title":"Intern Med"},{"key":"1822_CR15","doi-asserted-by":"crossref","unstructured":"Ishii Y, Yamada H, Sato T, Sue S, Kaneko H, Irie K, et al. Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers: a prospective, multicenter, two-arm, randomized controlled trial. Gastroenterol Res Pract. 2018;1615092.","DOI":"10.1155\/2018\/1615092"},{"key":"1822_CR16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/den.12857","volume":"29","author":"I Tsuchiya","year":"2017","unstructured":"Tsuchiya I, Kato Y, Tanida E, Masui Y, Kato S, Nakajima A, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial. Dig Endosc. 2017;29:576\u201383.","journal-title":"Dig Endosc"},{"key":"1822_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/den.12705","volume":"29","author":"D Maruoka","year":"2017","unstructured":"Maruoka D, Arai M, Kasamatsu S, Ishigami H, Taida T, Okimoto K, et al. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: a propensity score-matching analysis. Dig Endosc. 2017;29:57\u201364.","journal-title":"Dig Endosc"},{"key":"1822_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/00365521.2017.1410569","volume":"53","author":"Y Horikawa","year":"2018","unstructured":"Horikawa Y, Mizutamari H, Mimori N, Kato Y, Fushimi S, Sato S, et al. Short-term efficacy of potassium-competitive acid blocker following gastric endoscopic submucosal dissection: a propensity score analysis. Scand J Gastroenterol. 2018;53:243\u201351.","journal-title":"Scand J Gastroenterol"},{"key":"1822_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000485028","volume":"97","author":"A Yamasaki","year":"2018","unstructured":"Yamasaki A, Yoshio T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, et al. Vonoprazan is superior to rabeprazole for healing endoscopic submucosal dissection: induced ulcers. Digestion. 2018;97:170\u20136.","journal-title":"Digestion"},{"key":"1822_CR20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00464-018-6409-4","volume":"33","author":"EH Kim","year":"2019","unstructured":"Kim EH, Park SW, Nam E, Lee JG, Park CH. Comparative efficacy of various anti-ulcer medications after gastric endoscopic submucosal dissection: a systematic review and network meta-analysis. Surg Endosc. 2019;33:1271\u201383.","journal-title":"Surg Endosc"},{"key":"1822_CR21","doi-asserted-by":"publisher","first-page":"e15860","DOI":"10.1097\/MD.0000000000015860","volume":"98","author":"H Kang","year":"2019","unstructured":"Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: a systematic review with meta-analysis. Medicine (Baltimore). 2019;98:e15860.","journal-title":"Medicine (Baltimore)"},{"key":"1822_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00535-018-1487-6","volume":"54","author":"K Hamada","year":"2019","unstructured":"Hamada K, Uedo N, Tonai Y, Arao M, Suzuki S, Iwatsubo T, et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. J Gastroenterol. 2019;54:122\u201330.","journal-title":"J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01822-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T19:03:03Z","timestamp":1621710183000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01822-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01822-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of our hospital (Tsuyama Jihukai Ethics Committee) on March 3, 2015 (reference number 220) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was provided by all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}